Interius BioTherapeutics

Thank you to Philadelphia Business Journal and John George for the interview with Interius BioTherapeutics CEO Philip R. Johnson, MD and for spreading the good news in our Philadelphia biotech community about Interius's commitment to taking innovative therapies into the clinic. We appreciate the shoutout to Saar Gill, Interius's scientific co-founder, whose clinical experience inspired the development of our platform for precision delivery of genetic medicines. #phillybio #biotech #cellandgenetherapy #cart #genetherapy #celltherapy

Thank you to Jonathan D. Grinstein, PhD from Inside Precision Medicine for the publication on Interius BioTherapeutics this week highlighting our platform for precision delivery of genetic medicines and the achievement of the first patient dosed milestone with our lead program. The initiation of the Phase 1 trial for INT2104 is an important step in evaluating the safety of this in vivo CAR investigational product in adults with refractory/relapsing B cell malignancies. We remain thankful to everyone involved in the advancement of our science and programs and in amplifying our message across the biotech innovator community. #phillybio #biotech #cellandgenetherapy #cart #genetherapy #celltherapy

Today Interius BioTherapeutics announced that the first study participant has been dosed in INVISE, its first-in-human Phase 1 clinical trial of INT2104, a first-in-class gene therapy that delivers a CAR transgene to generate effector CAR-T and CAR-NK cells in vivo for the targeting of CD20-positive B cells for the treatment of B-cell malignancies. We are grateful for the dedication of all Interians, consultants, partners, and clinicians, who made this milestone a reality. #biotech #cellandgenetherapy #cart #genetherapy #phillybio #celltherapy See press release here: https://lnkd.in/duJA-fja

Interius BioTherapeutics is proud to sponsor the ASGCT Advancing Gene + Cell Therapies for Cancer in Philadelphia. Day 1 at the conference was outstanding: Dr. Daniel Powell opened with a reminder that we are Cellicon Valley, and the rest of the day lived up to that banner with presentations on all types of modalities and research ranging from non-clinical stage to meta-analyses of tens of trials. Thank you to the organizers and to Dr. Saar Gill for being a gracious host for the meeting! #ASGCTAdvancing24 #phillybio

Join Interius BioTherapeutics in Philadelphia next week! Our VP of R&D Tim Culp, PhD, is speaking at #ASGCTAdvancing24. He will be presenting a talk and joining a discussion on in vivo engineering of human immune cells on Oct. 17 at 8:30 a.m. Hope to see you there! #cellandgenetherapy #cart #genetherapy #phillybio #celltherapy

Listen to Tim Culp, PhD, our VP of Research and Development share his experience, wisdom, and passion for drug development on an Xtalks interview with Vera Kovacevic, PhD. Tim discusses our faster-better-cheaper platform for precision delivery of genetic medicines. While noting its immense future potential, Tim suggest "keeping an eye on the long view"—the ultimate goal is to get these new drugs through licensure and into the lives of patients. Interius BioTherapeutics has taken the first step: our first clinical trial is open and enrolling participants. #biotech #cellandgenetherapy #cart #genetherapy #phillybio #celltherapy

Tyler Menichiello, thank you for the shoutout to our Senior Director of Analytical Development, Jim Richardson! Jim moderated a panel and Elaine Youngman presented at the 16th Annual Bioprocessing Summit, highlighting Interius BioTherapeutics' deep expertise in complex CMC and analytics matters in the advanced therapies field with an eye on cost, practical solutions, and interactions with regulators.

Team Interius ‘Turned It Red’ in recognition of Blood Cancer Awareness Month by hosting dinner for 60+ patients and caregivers at American Cancer Society's Hope Lodge in Philadelphia! Because nothing says ‘comfort’ like a homecooked meal! From baked ziti and roasted chicken to brownies and a listening ear, our team showed up to serve! It was a very rewarding experience for the Interians who participated and were able to visit with guests over dinner. We are so very proud of our team and this initiative!

Glad to join the conversation at BioTechX USA these past couple of days in Philadelphia. Proud of the Interius BioTherapeutics team for sharing deep insights into IT systems, data capture, storage and architecture, and analytics workflows in support of rapid advancement of our therapeutic programs.

An excellent article, which interviewed our CEO Philip R. Johnson, MD, describes Interius BioTherapeutics as "one of the most advanced companies in this space". Thank you, Nature Magazine and Asher Mullard for recognizing Interius's progress and unique approach to in vivo CAR T therapy. We look forward to clinical data emerging over the next year and bringing important advancements to the field.